“multiple-myeloma” Archives

in
Entry Author Date Location
ASH 2018: Three Up, Two Down as Big Blood Disease Meeting Rolls On 12/03/18 National
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More 11/26/18 National
Allogene’s IPO Raises $288M for Tests of “Off-the-Shelf” Cell Therapy 10/11/18 San Francisco
Six Life Science Firms Close Q3 with an IPO, More Are on the Way 09/28/18 Boston
Bio Roundup: CRISPR Ruling, “America’s Nobels,” IPOs & More 09/14/18 National
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs 08/30/18 San Francisco
ASCO Wrap: Cancer Combos, Precision Meds, Stock Movers & More 06/05/18 National
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results 05/29/18 San Francisco
With New Data, Karyopharm Says It Will Ask for Myeloma Approval 04/30/18 Boston
Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More 03/30/18 National
With $20B to Spend, Sanofi, Celgene Bet Big on Hemophilia, CAR-T 01/22/18 National
Cellectar Biosciences Shutting Down Manufacturing Operations 01/08/18 Wisconsin
Bio Roundup: Tax Cuts, a Funding Rush, Hemophilia Questions & More 12/15/17 National
ASH 2017 Highlights: CAR-T Competition, Myeloma, Hemophilia & More 12/11/17 National
Promega, Cellectar, Blockchain, & More: This Week’s WI Watchlist 12/08/17 Wisconsin
Gilead Bets on Cell Therapy Again with $567M Cell Design Labs Deal 12/07/17 San Francisco
Bio Roundup: RNAi Drama, Immunotherapy Data, Lasker Winners & More 09/08/17 National
Immunotherapy Safety Worries Halt Celgene Myeloma Study, Slow 5 Others 09/07/17 New York
To Be More Than Quick Splash, Gilead’s CAR-T Purchase Faces Hurdles 08/28/17 San Francisco
Celgene Narrows Its Relationship With Sutro, No Acquisition Coming 08/10/17 New York
Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps 07/28/17 National
In a Myeloma Setback, Merck Halts Studies Due to Patient Deaths 06/12/17 New York
Dragonfly, Tyler Jacks’s Disney-Backed Startup, Gets $33M in Celgene Deal 06/12/17 Boston
Keeping Focus on Cancer, Karyopharm Licenses Antiviral to Anivive 05/04/17 Boston
AACR Review: Biden Fired Up, Incyte Doubles Up, BMS Up And Down 04/06/17 National
Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed? 03/13/17 National
WARF, Cellectar Expand Licensing Agreement For Blood Cancer Drug 03/10/17 Wisconsin
After Navigating Ups and Downs, Cellectar CEO Caruso Looks to Future 02/21/17 Wisconsin
Lynx Bio Makes Headway on New Diagnostic for Blood Cancer Drugs 02/13/17 Wisconsin
Cellectar Awarded Another Cancer Drug Patent 01/26/17 Wisconsin
Page 2 of 5 « previous page · next page »